A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2012Cited by 69
Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and EfficacyThomas Van Looy, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2014Cited by 50
Supplementary Figure 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Supplemental Figures Legend from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and EfficacyThomas Van Looy, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Table S2 from Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and EfficacyThomas Van Looy, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0